Quick Answer
Vanda Pharmaceuticals Inc. reported Operating Income of -$151.17 million for fiscal year 2025.
Vanda Pharmaceuticals Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$151.17M | -271.8% |
| 2024 | -$40.66M | -191.4% |
| 2023 | -$13.95M | -320.4% |
| 2022 | $6.33M | -85.0% |
| 2021 | $42.16M | +54.8% |
| 2020 | $27.24M | +19.4% |
| 2019 | $22.81M | +4.9% |
| 2018 | $21.74M | +228.6% |
| 2017 | -$16.90M | +9.0% |
| 2016 | -$18.57M | +53.8% |
| 2015 | -$40.19M | -300.3% |
| 2014 | $20.06M | +194.6% |
| 2013 | -$21.20M | +27.3% |
| 2012 | -$29.18M | -172.5% |
| 2011 | -$10.71M | -221.1% |
| 2010 | $8.84M | +124.6% |
| 2009 | -$35.95M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$31.28M | -184.4% | +18.7% |
| June 30, 2025 | -$38.50M | -279.5% | +6.2% |
| March 31, 2025 | -$41.03M | -344.3% | -273.0% |
| September 30, 2024 | -$11.00M | -83.5% | -8.4% |
| June 30, 2024 | -$10.15M | -253.9% | -9.9% |
| March 31, 2024 | -$9.23M | -560.8% | -54.0% |
| September 30, 2023 | -$6.00M | -253.4% | -109.1% |
| June 30, 2023 | -$2.87M | -182.8% | -243.1% |
- Vanda Pharmaceuticals Inc. showed a decrease of -271.8% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, Vanda Pharmaceuticals Inc.’s operating income has declined by 320.5% (from -$35.95 million to -$151.17 million).
- The most recent figure is from Vanda Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: